Biotech Analyst Harrison discusses compounded Bevacizumab use today and what changes, should ONS-5010 be approved by the FDA, on an Analyst/Industry conference call to be held on March 7 at 1 pm. Webcast Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on OTLK:
- BTIG biotechnology analyst to hold an analyst/industry conference call
- Outlook Therapeutics announces anticipated milestones
- Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2023 and Provides Corporate Update
- Outlook sees cash runway through anticipated FDA approval of ONS-5010
- Outlook Therapeutics reports Q1 EPS (8c), consensus (5c)